Introduction
Oncogenic proteins alter gene expression patterns during cellular transformation. DNA binding oncoproteins like c-MYC and FRA-1 have been shown to promote cell growth by activating specific sets of genes (1, 2) . Antioncogenic proteins reverse these processes to restore normal cell growth. We have been studying the mechanisms of antitumor action of IFN-h and retinoic acid (IFN/ RA) in human tumor cells. IFN/RA exhibited strong antitumor actions in a number of animal models and in clinical studies (3, 4) . Using a genetic technique, we have isolated a novel gene product, gene associated with retinoid-IFN-induced mortality 19 (GRIM-19), which promotes IFN/RA-induced cell death (5) . More recently, we have shown that a loss of GRIM-19 expression in human renal cell carcinomas (6) and an inhibition of its proapoptotic activity by viral oncoproteins occur, indicating a potential tumor suppressorlike function for this protein. Overexpression of GRIM-19 in a number of human tumor cell lines induces apoptosis (5) (6) (7) . Some esophageal tumors seem to harbor inhibitors of GRIM-19 (8) . A portion of the total GRIM-19 in cells is also present in the mitochondrion (9) (10) (11) . Very recently, GRIM-19 has been coupled to reactive oxygen species generation in an IFN/RA-induced pathway in HeLa and MCF-7 cells (12) .
We and others have shown that GRIM-19 binds to signal transducer and activator of transcription 3 (STAT3) transcription factor and inhibits STAT3-dependent cytokine-induced gene transcription (13, 14) . However, its role in regulating oncogenic cell proliferation and, in particular, its effects on a ligandindependent, constitutively active STAT3 and cellular transformation are unclear. To address these issues, we have used a cellular system in which a constitutively active STAT3 was sufficient to induce oncogenic transformation (15) . We show here that GRIM-19 overrides cellular transformation caused by constitutive STAT3 and suppresses the expression of endogenous genes involved in cell proliferation. GRIM-19 also inhibits injury-induced cell migration and formation of tumors in vivo. These data for the first time show a direct tumor-suppressive effect of GRIM-19 and establish an ''oncogene-tumor suppressor'' like relationship between STAT3 and GRIM-19.
Materials and Methods
Plasmids and antibodies. The pRC/CMV flag-STAT3C (A 661 C and N 663 C) that expresses a constitutively dimerizing version of STAT3 (15) was a gift from Jackie Bromberg (Sloan-Kettering Cancer Center, New York, NY). Mammalian expression vector pCXN2-myc and its derivative pCXN2-GRIM-19-myc were described elsewhere. TKS3-Luc, cyclinB1-Luc, and cdc2-Luc were described in our previous publication (14) . APRE-Luc contains three copies of acute phase response element (APRE) upstream of the SV40 minimal promoter. c-fos-Luc (16) and Bcl-X L -Luc (17) were described earlier. Lentiviral expression vectors carrying GRIM-19 and a scrambled short hairpin RNA (shRNA) were purchased from Open Biosystems, Inc., and virus stocks were prepared as recommended by the supplier. Antibodies specific for STAT3, phospho-STAT3-Y705, and phospho-STAT3-S727 (Cell Signaling Technology); actin, myc-epitope, and Flag-epitope (SigmaAldrich); and Ki-67 (Oncogene Science) were used in these studies.
Establishment of stable cells. Rat fibroblast 3Y1 cells were grown in DMEM supplemented with 10% heat fetal bovine serum (FBS), 100 units/mL penicillin, and 100 Ag/mL streptomycin. Cells were electroporated either individually or in combination with pCXN2-myc, STAT3C, or pCXN2-GRIM 19 (1 Ag of each plasmid) using the Nucleofector technology (Amaxa Biosystems). Transfection efficiency was f45% with this method. Twentyfour hours posttransfection, cells were selected with G418 (750 Ag/mL) for 10 to 12 days. Drug-resistant clones were isolated and expanded. All gene expression studies were conducted using pools of colonies (n = 150) to avoid a clonal bias.
Immunoblotting. An equal amount of total protein was resolved by 10% SDS-PAGE. Proteins were transferred to polyvinylidene difluoride membrane and probed with specific antibodies. Blots were developed using enhanced chemiluminescence reagent (Pierce).
Gene expression and reporter analyses. Total RNA was extracted using RNA-Bee reagent (Tel-Test, Inc.) as recommended by the manufacturer. Primers for reverse transcription-PCR designed for different genes are presented in the table. About 5 Ag of total RNA were reverse transcribed using a commercially available Superscript enzyme (Invitrogen, Inc.). A portion of cDNA from each reaction was used for PCR using the following conditions: each cycle consisted of denaturation at 95jC for 30 s, annealing at 55jC for 30 s, extension at 72jC for 30 s, and a final extension at 72jC for 5 min.
Quantitative real-time PCR was done using a Stratagene MX3005P realtime PCR machine. For all samples, RT PCR amplifications were done in a final volume of 30 AL (20 ng of cDNA, 200 Amol/L of primers, 0.4 unit of thermal DNA polymerase IDPOL, and 0.1Â SYBR Green). PCR was carried out using the following cycling conditions: a hot start at 95jC for 10 min, followed by 40 cycles of 95jC for 30 s and 55jC for 30 s. The mRNA coding for the ribosomal protein L32 (rpl 32) was used as an internal control. Expression of different genes was normalized to rpl 32 and C t values (threshold cycle) were estimated. Mean relative abundance of each transcript was calculated. All reactions were done in triplicate. Each experiment was repeated for three separate batches of RNAs. Primers for quantitative real-time PCR were shown in Table 1 .
Cells were transfected with different luciferase reporters along with a h-actin-h-galactosidase plasmid using the Lipofectamine plus reagent as described earlier (14) . Luciferase activity was normalized to that of h-galactosidase. All experiments were repeated at least thrice. Chromatin immunoprecipitation was carried out using commercially available kits (Upstate Biotech) as described earlier (18) . Primers used for specific genes are listed in Table 1 .
Soft-agar colony formation assay. For soft-agar assays, bottom layer containing 0.7% agarose with growth medium plus 10% fetal bovine serum was poured into six-well plates. Then, 10,000 cells were mixed with 0.35% agarose in DMEM containing 10% FBS and plated onto the existing agar layer. Plates were incubated for f3 weeks in a humidified incubator at 37jC. The colonies were counted in four to five random fields from each of the duplicate samples by using a microscope at Â100 magnification.
In vitro wound healing assay. 3Y1 cells stably expressing various plasmids were grown in DMEM with 5% FBS and penicillin-streptomycin in a six-well dish. Confluent monolayer was scratched with a 200-AL pipette tip to make a wound. The monolayer was washed twice with PBS and then supplemented with medium and incubated for 4 h at 37jC. Cell migration into wounded area was followed microscopically. Images were captured at the interface of unwounded and wounded areas. At least quadruplicates were used per cell line. These experiments were repeated thrice.
Cell migration assays. Cell migration assay was done using Transwell chambers (6.5-mm diameter, 8-Am pores, Transwell; Costar Corp.) containing a polycarbonate membrane. The lower chamber was filled with 0.6 mL of DMEM with 10% FBS; the upper portion of insert is filled with 25,000 cells in 0.1-mL DMEM without serum and incubated at 37jC for 24 h. Nonmigrated cells in the upper membrane surface were removed gently with a cotton swab and the migrated cells attached to bottom surface of the membrane were fixed with ice-cold 100% methanol and stained with 0.01% crystal violet in 20% ethanol. The number of migrated cells was determined by dye elution with 5% acetic acid and 5% methanol; absorbance was measured at 595 nm. In parallel, some membranes were stained similarly without the removal of nonmigrated cells for each cell line. The absorbance data from these controls provided a measure of the total number of cells plated in that well. Absorbance obtained with the migrated cells (experimental wells, where nonmigrated cells were removed) was expressed as a percent of total number of cells in each case. 3Y1 cells without any transfection were used as a baseline for these experiments (100%). All experiments were done thrice in triplicate. 
Fwd: 5 ¶-TGGACCTCTCGTCACTTCGGTC-3 ¶ 219 Rev: 5 ¶-GAAAGTACTTGATATAATAACG-3 ¶ Tumorigenic assays. These assays were conducted as described earlier (3) . Three-to four-week-old athymic nude (nu/nu) NCr mice (Taconic) were used in the study. Procedures involving animals and their care were conducted in conformity with the institutional guidelines that are in compliance with national and international laws and policies ( ) were inoculated into flanks in the mid-axillary line. Tumor volume was calculated using caliper measurements and the formula for a prolate spheroid: V = (4/3) Â pa 2 b, where 2a is the minor axis and 2b is the major axis of prolate spheroid. Student's two-tailed t test was used to assess the statistical significance of difference between pairs of means of tumor volume. Tumor specimens were fixed, sectioned, and stained with various antibodies using a commercially available Vectastain ABC kit (Vector Labs).
Results
GRIM-19 inhibits cell growth in cell lines expressing high levels of STAT3. To determine the antitumor effects of GRIM-19, we have used a human prostatic cell line, PC3. This cell line has been shown earlier to express STAT3 at higher levels compared with normal prostatic epithelium (19) . In addition, STAT3 in this cell line is constitutively phosphorylated at the Tyr 705 residue. An empty mammalian expression vector, pCXN2, or its derivative expressing GRIM-19 as a myc-tagged protein was electroporated into these cells and cells were selected with G418. Following selection for 3 weeks, the surviving cell colonies were fixed and counted. As shown in Fig. 1A and B, GRIM-19 significantly decreased the colony formation by PC3 cells. Similar effects of GRIM-19 were observed when these transfectants were grown on soft agar (data not shown). Similar results were obtained with another prostate cancer cell line, LnCaP, indicating a general antitumor effect of GRIM-19 (data not shown). In addition, we have shown a similar effect of GRIM-19 on MCF-7, BT-20, T47D (breast carcinoma), HeLa, and ACHN (renal cell carcinoma) cells in other reports (5-7), indicating its global inhibitory effect on a number of tumor cell lines. We transfected these cells with TKS3-Luc, a reporter that responds to the transcriptional activity of STAT3, to determine the effect of GRIM-19 on STAT3-induced transcription (Fig. 1C) . A significantly lower Luc activity was noted in the presence of GRIM-19 compared with the empty vector control. In contrast, GRIM-19 had no discernible effect on cytomegalovirus (CMV) enhancer-driven expression of luciferase (Fig. 1D) . Thus, GRIM-19 seems to ablate constitutive STAT3 activity in these cells.
Effect of GRIM-19 on STAT3C-induced cellular transformation. Because the above cancer cell lines may have undergone several genetic changes including a constitutive up-regulation of STAT3, we examined next if these effects were truly directed against STAT3-mediated cellular transformation and downstream biological activities. Therefore, we used the rat fibroblastic cell line 3Y1 for these experiments because it has a lower frequency of spontaneous transformation compared with the NIH 3T3 cell line. This cell line does not form tumors on its own, unless transformed by a potential oncogene. Cells were transfected with a genetically engineered STAT3-mutant, S3C, which could spontaneously dimerize independently of its tyrosine residue. The constitutive dimerization of this protein is mediated by a disulfide bond formed between cysteine residues (15) . We also coexpressed GRIM-19 to determine its effect on S3C-induced cellular transformation. Transfection of S3C into cells caused a robust cellular transformation, as revealed by numerous soft-agar colonies ( Fig. 2A and B) . In the presence of GRIM-19, significantly (P > 0.001) fewer S3C-dependent soft-agar colonies were observed. These colonies were distinctly smaller in size than those formed by S3C transfection. Neither the empty vector (pCXN2) nor GRIM-19 alone had an effect on cellular transformation. Thus, GRIM-19 suppresses S3C-induced cellular transformation.
Because the above experiment shows the effects only of cotransfected GRIM-19 on cellular transformation, we stably transfected a GRIM-19 expression vector into a 3Y1 cell line that was previously transformed with S3C. This cell line was a pool of several S3C-expressing colonies. The resultant colonies were used for the formation of soft-agar colonies and cell growth assays. To avoid a clonal bias, all experiments used pools of stable colonies. As expected, the S3C transformants formed large soft-agar colonies. Transfection of GRIM-19, but not the empty vector, into these cells caused a marked reduction in the number of soft-agar colonies (Fig. 2C) . We have also ascertained the expression of S3C and GRIM-19 in these cells (Fig. 2D) . Because the S3C protein is flag tagged, we detected its expression with a flag-specific antibody. A 95-kDa protein corresponding to S3C was detected only in cells transfected with S3C expression vector but not in those transfected with pCXN2 and GRIM-19 alone. We observed a higher amount of S3C protein in cells carrying both GRIM-19 and S3C. We presume it to be due to an enrichment of high S3C-expressing cells in the pools following transfection with GRIM-19. It is possible that the low S3C expressors in this pool may have died due to the proapoptotic activity of GRIM-19. As expected, the myc-tagged GRIM-19 protein was detected in cells transfected with pCXN2-GRIM-19 myc only. A comparable loading of protein was ensured by probing these blots with actin-specific antibodies. Consistent with its inhibitory effect on colony formation, the myc-GRIM-19 protein coimmunoprecipitated the constitutive STAT3 protein.
We next checked the status of tyrosine and serine phosphorylation in these cells (Fig. 2E ). As expected, there was no constitutive tyrosine phosphorylation of S3C. The positive control [interleukin-6 (IL-6)-treated MCF-7 cell extract] showed normal tyrosine phosphorylation. There was no difference in phosphorylation of 
STAT3 Ser
727 among various transfectants. The steady-state serine phosphorylation of STAT3 is also found in many other cell types (20) . As anticipated, a higher amount of total STAT3 was seen in the S3C transfectants, which reflects the STAT3 protein derived from endogenous gene and the transfected plasmid. We have also determined its constitutive nuclear presence by a gel-mobility shift assay with a STAT3 binding element as a probe and nuclear extracts from the S3C-and S3C/G19-transfected cells and by a Western blot analysis of the same nuclear extracts (Supplementary Figs. S1 and S2). In contrast, the endogenous STAT3 in 3Y1 cells expressing either an empty vector or GRIM-19 translocated to the nucleus only after IL-6 stimulation. Importantly, GRIM-19 did not significantly affect either the IL-6-induced nuclear translocation of endogenous STAT3 or the ligand-independent S3C in these cells.
GRIM-19 inhibits cell injury-and mitogen-driven migration of S3C-expressing cells. We next used these cells for injuryinduced and mitogen-induced transwell migration assays. In the injury-induced migration assays, an incision was introduced into a confluent monolayer of cells growing in a dish. Cell migration into the ''denuded'' area was monitored 4 h later. As shown in Fig. 3A , little or no cells migrated into the injured area when cells were expressing GRIM-19 or pCXN2. However, a number of S3C transfectants migrated under the same conditions. Such rapid migration was virtually absent in cells expressing GRIM-19. By 18 h, all cell lines reached confluence (data not shown). These data clearly show that the presence of S3C promotes rapid cell motility.
Cell motility was also assessed using another strategy. Cells were grown in Boyden chambers and their transwell migration toward growth medium was monitored by a colorimetric assay (Fig. 3B) . In these experiments, cellular migration obtained with naïve 3Y1 cells (control) was considered as 100% and the data obtained with experimental samples were expressed as a percentage of control migration. As shown in the figure, a significant (P > 0.01) percentage of cells expressing S3C migrated in these assays compared with the vector alone-transfected cells. GRIM-19 completely suppressed S3C-dependent migration. GRIM-19 alone did not have any statistically different effect on cell motility.
Lastly, cells expressing S3C and GRIM-19 combinations were also used for growth assays using sulforhodamine B staining as previously described. Cell growth was monitored after 3 days (Fig. 3C) . On day 0 (7 h after plating the cells), the total numbers of initially plated cells were comparable. However, the S3C-transfected cells grew robustly compared with the pCXN2-or GRIM-19 alonetransfected 3Y1 cells. In the presence of GRIM-19, the rapid growth induced by S3C was significantly (P > 0.005) reduced.
GRIM-19 suppresses the transcriptional induction of a number of S3C-regulated genes. We next investigated the molecular basis for the loss of cell growth function. Previous studies in human cell lines have shown an up-regulation of a number of genes involved in growth control. We have selected five genes for these studies whose rodent homologues are known. The relative expressions of the mRNAs of these genes were quantified using quantitative real-time PCR. Two of these genes, fas (a death receptor) and pyruvate dehydrogenase kinase 4 (pdk4; a protein kinase involved in the regulation of carbohydrate metabolism), are down-regulated in tumor cells expressing high STAT3. Three others, c-myc, cyclin b1, and superoxide dismutase 2 (sod2), are implicated in tumor cell proliferation. The expression of cyclin B1 (Fig. 4A) , c-myc, and sod2 ( Supplementary Fig. S4A ) was increased over the control levels severalfold (2.5-to 3.5-fold depending on the gene) in the presence of S3C. GRIM-19 inhibited the S3C-dependent increase Figure 3 . Effect of GRIM-19 on S3C-dependent migration of cells to wounded area in various cell lines (A). Magnification, Â100. Note the rapid migration of S3C-expressing cells, but not the controls, into the wounded area. These experiments were repeated thrice. Quadruplicate plates were used per cell line. A representative figure is shown. The vertical line in each photograph shows the edge of injured site. B, invasion assay was done using Transwell inserts. Ten percent serum was used as an attractant in the lower chamber of a 24-well tissue culture dish. Cells (25,000) were seeded in the upper chamber of insert and incubated for 24 h; migrated cells were fixed, stained with crystal violet, and the bound dye was eluted and quantified at 595 nm. Absorbance obtained with 3Y1 cells was used as 100%. C, growth of various cell lines as measured by a colorimetric assay with sulforhodamine B. n = 8 per cell line per time point.
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Cancer Res 2007; 67: (13 in the expression of these genes. These levels were comparable to those expressing GRIM-19 alone. In the case of c-myc, GRIM-19 caused a stronger repression of the S3C-induced expression of the gene, even below the baseline level. A converse picture was seen with fas ( Fig. 4A) and pdk4 mRNAs (Supplementary Fig. S4A ). The expression of both these mRNAs was significantly (P > 0.01) repressed in the presence of S3C. GRIM-19 alone did not have an effect on these genes. However, GRIM-19 reversed the negative regulatory effects of S3C on these genes. Thus, GRIM-19 caused a reversion of S3C-transformed cells to a pretransformed state with respect to certain gene expression.
To show that these are indeed transcriptional effects of GRIM-19, we transfected luciferase reporter plasmids driven by the native promoters of four STAT3 regulated genes, cyclin b1 (Fig. 4A) , cdc2, c-fos, and bcl-x L (Supplementary Fig. S4B ), into 3Y1 cell lines expressing pCXN2, S3C, GRIM-19, and S3C/GRIM-19 and measured gene expression. Two others reporters, S3-Luc and APRE-Luc, are driven by minimal S3 binding elements to which STAT3 binds (Table 1) were used for immunoprecipitating the formaldehyde cross-linked soluble chromatin after treatment with IFN/RA. PCR was carried out with gene promoter-specific primers (indicated on the left) using the Immunoprecipitated genomic DNA as a template (30 cycles). For input controls (column C1 ), soluble chromatin (1/100 of sample used in reactions shown in columns C1 and C3) was used as a template without immunoprecipitation. NR IgG, normal rabbit IgG (control for STAT3 antibodies). IgG2a, mouse IgG2a (control for GRIM-19 antibodies). Western blot and immunoprecipitation analyses of the PC3 cell lysates were conducted with the indicated antibodies.
( Supplementary Fig. S4B ). The expression of all reporters was induced severalfold by S3C. In every case, GRIM-19 overrode S3C-induced transcription of the reporter. Notably, it was lowered below the vector alone-transfected lines. To show that this is a true effect of GRIM-19, cells were transfected with lentiviral shRNA expression plasmids capable of targeting GRIM-19 into S3C/GRIM-19. Two reporters, cyclin B1-Luc (Fig. 4B ) and cdc2-Luc ( Supplementary Fig. S4C ), were used for these experiments. As expected, the control vector lacking GRIM-19 sequences and scrambled GRIM-19 sequence were unable to reinstate S3C-driven transcription of both reporters (Fig. 4B) . However, the lentiviral vector carrying GRIM-19-specific shRNA restored S3C-driven transcription of these reporters. These data confirm that no other genetic changes other than that of GRIM-19 are responsible for the repression of S3C-driven transcription. We have also confirmed the knockdown of the expression of transfected GRIM-19, but not that of S3C or actin, in these cells by GRIM-19-specific shRNA (Fig. 4B) . The scrambled control and empty vector did not have any effect on GRIM-19 expression.
We next checked if the gene-repressive effects of GRIM-19 were due to a recruitment of GRIM-19 to the STAT3-regulated gene promoters. We examined these aspects in the human tumor cell line PC3 in which endogenous STAT3 is constitutively active and is located in the nucleus. Because the gene promoters and their sequences of most STAT3-induced genes in rat cells have not been well characterized, we carried out these studies in a human cell line. Furthermore, GRIM-19 inhibits STAT3-driven transcription in these cells (Fig. 1) . These cells were treated with IFN/RA, a well-known inducer of GRIM-19 (5, 14) , for various lengths of time. Chromatin was cross-linked with formaldehyde, and soluble chromatin was immunoprecipitated with GRIM-19-specific or isotype control antibodies. The immunoprecipitation products were used for PCR with gene-specific primers (Fig. 4C) . As expected, GRIM-19-specific immunoglobulin G (IgG), but not the isotype control IgG2a, immunoprecipitated the bcl-x L , bcl-2, and cyclin b1 gene promoters. More importantly, GRIM-19 recruitment to these promoters was induced in response to IFN/RA. These differences in GRIM-19 recruitment to these gene promoters do not seem to be due to variations in the amounts of total chromatin input into these reactions (Fig. 4C) . We also checked the recruitment of STAT3 to these promoters. As expected, STAT3 is constitutively present at these promoters, as revealed by immunoprecipitation of these gene promoters by STAT3-specific IgG but not normal rabbit IgG. Thus, IFN/RA-induced recruitment of GRIM-19 to the STAT3-dependent gene promoters seems to repress these genes. This seems to occur due, in part, to an IFN/RA-induced expression of GRIM-19. STAT3 levels did not significantly change under these conditions. Consistent with these observations, endogenous GRIM-19 interacted with endogenous STAT3 following IFN/RA treatment.
In vivo effects of GRIM-19 on tumor suppression. To determine if S3C-transformed cells have differential abilities to form tumors in the presence of GRIM-19, 3Y1 cell lines carrying various expression vectors were transplanted into athymic nude mice and tumor formation was monitored over a period of 25 days. As shown in Fig. 5A , S3C-transformed cells formed large tumors, which grew robustly compared with 3Y1 cells transfected with pCXN2. GRIM-19 significantly knocked down the ability of S3C to form tumors (P > 0.001). Remarkably, GRIM-19 even depressed the baseline tumor formation by 3Y1 cells (P > 0.01). We also examined the cellular bases for the loss of tumor formation by examining the intratumoral levels of proliferation-associated antigen Ki-67, STAT3, and GRIM-19 using specific antibodies to these proteins (Fig. 5B) . The S3C tumors were highly positive for Ki-67. The tumors carrying GRIM-19 were weakly positive for STAT3 and Ki-67. More importantly, the S3C/GRIM-19 tumors have an extremely Although the presence of S3C augmented mitogen-and injuryinduced motility in vitro (Fig. 3) , tail vein injection of 3Y1 cells carrying S3C did not cause significant metastases in this model (data not shown). It is possible that these cells may not have acquired other metastatic characteristics required for in vivo motility, such as extravasation through blood vessels.
To examine the antitumor effect of GRIM-19 to a human tumor, PC3 cells, which express high STAT3, were stably transfected with GRIM-19 and used for tumor formation assays in vivo (Fig. 5C) . Unlike 3Y1-tumors, PC3 tumors form at a slower pace. Therefore, we monitored tumor development over a period of 11 weeks. The PC3 line expressing pCXN2 formed large tumors, which significantly differed from GRIM-19-expressing tumors in terms of growth pattern as early as 3 weeks after initial transplantation. By the end of 7 weeks, the PC3 tumors were 6-fold bulkier than the GRIM-19-expressing tumors. To examine their metastatic activity, these cells (1 Â 10 5 per mouse) were injected into mice via the tail vein. In these experiments, 10 mice per group were used. In these assays, the PC3 cells formed a total of 24 and 11 metastases in the liver and kidney tissues, respectively, per group (Supplementary Table S1 ). Only one mouse did not show any metastases in this group. Metastases occurred in liver and kidney of the same mouse. No metastases were found in other tissues. In contrast, the same number of GRIM-19-transfected PC3 cells formed five and two metastases in the liver and kidney, respectively, per group. About 50% of the mice injected with cells expressing GRIM-19 did not develop any metastases.
Discussion
STAT3 is a major transcription factor for mediating cytokine responses, and its inactivation in experimental animals leads to the development of several pathologies including embryonic lethality (20) . In most cases, cytokine-induced transient phosphorylation of STAT3 at Tyr 705 and Ser 727 is sufficient for driving these responses (20) . A feedback inhibition of JAKs by STAT3-induced suppressor of cytokine signaling (SOCS)-3 protein (21), dephosphorylation at Y705 (22) , and nuclear export of STAT3 (23) seems to prevent incessant expression of STAT3-dependent genes in normal cells. In contrast to these scenarios, STAT3 is constitutively activated in a number of human tumor cell lines and primary tumors, where activated oncogenes have been suspected to induce uninterrupted tyrosine phosphorylation of STAT3 (24) . The most convincing evidence for an ''oncogenic STAT3'' comes from a recent study of npm-alk oncogene, which obligatorily depends on STAT3 for cellular transformation in lymphocytes (25) . Whereas excessive tyrosine phosphorylation by oncogenes is one side of the coin, it does not provide a full picture of the events occurring during STAT3-dependent tumor growth promotion. It is conceivable that inactivation of STAT3 inhibitors is also a major step involved in ''pushing'' the cell into a transformed state, and a mere tyrosine phosphorylation alone may be insufficient. Lastly, the ability of STAT3-Y705F mutant to activate gene transcription by simple overexpression in nontransformed cells also indicates the potential tyrosine phosphorylation-independent mechanisms of cell proliferation (26) . Thus, the roles of STAT inhibitors in cellular transformation have been poorly investigated. To date, three STAT3 inhibitors, SOCS3, protein inhibitor of activated STAT3 (PIAS3; ref. 27) , and GRIM-19 (5), have been identified. Apart from the observations that socs3 gene expression is inhibited due to methylation in some non-small-cell lung cancers (28) , hepatomas (29) , and head and neck cancers (30) , there is no direct experimental proof that these SOCS proteins counteract the constitutive STAT3 in tumors. PIAS3 seems to act more like a SUMO ligase to regulate the function of steroid receptors than STAT3 itself (31) (32) (33) . Thus, it is conceivable that the transiently (normal) and chronically (tumors) active states of STAT3 can be regulated by different inhibitors.
Using a genetic strategy, our lab has isolated a novel gene product, GRIM-19, whose inactivation promotes cell growth, and its overexpression induces growth arrest and apoptosis in a number of cell types (5) . GRIM-19 is present in both cytoplasmic and nuclear compartments (5, 14) . A first indication that GRIM-19 may be an antioncogenic protein came from observations that DNA viral oncoproteins such as vIRF1, human papillomavirus-E6, and SV40 T antigen inhibit GRIM-19-driven apoptosis (34) . Subsequent studies by others have shown the presence of GRIM-19 inhibitors in some esophageal tumor cell lines (8) and the occurrence of mutations in the gene coding for GRIM-19 in some thyroid cancers (35) . Using mass spectrometric approaches, we have recently shown the loss of GRIM-19 expression in a number of primary renal cell carcinomas (6) . We and others have isolated STAT3 as a GRIM-19 binding protein using a yeast two-hybrid screen and showed that GRIM-19 inhibits cytokine-induced STAT3-driven gene expression (13, 14) . Whereas most of these studies point out a potential role for GRIM-19 as an antioncogenic protein, no direct evidence for it in cellular transformation has been presented.
Here, we have used a model in which an experimentally engineered constitutive STAT3, S3C, alone transforms cells in culture. In this model, the single genetic change that transforms cells is S3C. We have used several different methods including softagar growth assays, injury-and mitogen-induced cell migration, and in vivo growth of tumor cells as indices for its direct antitumor actions ( Fig. 5 and Supplementary Table S1 ). More importantly, GRIM-19 was able to reverse the gene expression program in S3C-transformed cells quite significantly, as evidenced by repression of a number of proliferation-associated genes, identified in gene expression profiling studies as genes regulated by STAT3 (26, 36) , and by derepression of antigrowth genes such as Fas (Figs. 4A and Supplementary Fig. S4A ). Because STAT3 is known to activate the genes involved in cell proliferation and inhibition of apoptosis, the GRIM-19 effects on STAT3C-induced cell growth are probably exerted through an inhibition of these processes. These results are consistent with other reports that the fas gene is repressed by STAT3 (36) and IFN/RA treatment induces Fas and Fas ligand expression in cells (37) , which can suppress tumor growth. Indeed, the presence of GRIM-19 augmented Fas-mediated apoptosis in the S3C-expressing cells (see Supplementary Fig. S3 ). Interestingly, a metabolic regulatory enzyme, PDK4, is also repressed by S3C, and GRIM-19 restores its expression (Supplementary Fig. S4 ). PDK4 inactivates the mitochondrial pyruvate dehydrogenase complex (PDHc) via a direct phosphorylation of its subunits (38) . At this stage, it is not clear why S3C suppresses this gene. It may have an undefined relationship to altered glucose metabolism in aggressively growing tumors, wherein glycolytic generation of ATP supersedes that of tricarboxylic acid cycle-dependent oxidative phosphorylation (39) . Indeed, c-myc, a target of STAT3, drives up the expression of glycolytic enzymes (40) . There are no known STAT3 binding sites in the promoters of human and rodent pdk genes (41); hence, the GRIM-19-dependent relief of STAT3-induced inhibition of this gene must occur in an indirect manner. That said, we have also shown
